Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91


Mismatch repair deficient hematopoietic stem cells are preleukemic stem cells.

Qing Y, Gerson SL.

PLoS One. 2017 Aug 2;12(8):e0182175. doi: 10.1371/journal.pone.0182175. eCollection 2017.


RUNX1-ETO and RUNX1-EVI1 Differentially Reprogram the Chromatin Landscape in t(8;21) and t(3;21) AML.

Loke J, Assi SA, Imperato MR, Ptasinska A, Cauchy P, Grabovska Y, Soria NM, Raghavan M, Delwel HR, Cockerill PN, Heidenreich O, Bonifer C.

Cell Rep. 2017 May 23;19(8):1654-1668. doi: 10.1016/j.celrep.2017.05.005.


ASXL2 is essential for haematopoiesis and acts as a haploinsufficient tumour suppressor in leukemia.

Micol JB, Pastore A, Inoue D, Duployez N, Kim E, Lee SC, Durham BH, Chung YR, Cho H, Zhang XJ, Yoshimi A, Krivtsov A, Koche R, Solary E, Sinha A, Preudhomme C, Abdel-Wahab O.

Nat Commun. 2017 May 18;8:15429. doi: 10.1038/ncomms15429.


Dysregulation of haematopoietic stem cell regulatory programs in acute myeloid leukaemia.

Basilico S, Göttgens B.

J Mol Med (Berl). 2017 Jul;95(7):719-727. doi: 10.1007/s00109-017-1535-3. Epub 2017 Apr 20. Review.


Biology and relevance of human acute myeloid leukemia stem cells.

Thomas D, Majeti R.

Blood. 2017 Mar 23;129(12):1577-1585. doi: 10.1182/blood-2016-10-696054. Epub 2017 Feb 3. Review.


The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia.

Sperling AS, Gibson CJ, Ebert BL.

Nat Rev Cancer. 2017 Jan;17(1):5-19. doi: 10.1038/nrc.2016.112. Epub 2016 Nov 11. Review.


Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities.

Stahl M, Kim TK, Zeidan AM.

World J Stem Cells. 2016 Oct 26;8(10):316-331. Review.


DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders.

Sato H, Wheat JC, Steidl U, Ito K.

Front Oncol. 2016 Aug 22;6:187. doi: 10.3389/fonc.2016.00187. eCollection 2016. Review.


Mechanisms determining the fate of hematopoietic stem cells.

Lin S, Zhao R, Xiao Y, Li P.

Stem Cell Investig. 2015 May 15;2:10. doi: 10.3978/j.issn.2306-9759.2015.05.01. eCollection 2015. Review.


Could Vitamin D Analogues Be Used to Target Leukemia Stem Cells?

García-Ramírez I, Martín-Lorenzo A, González-Herrero I, Rodriguez-Hernández G, Vicente-Dueñas C, Sánchez-García I.

Int J Mol Sci. 2016 Jun 6;17(6). pii: E889. doi: 10.3390/ijms17060889. Review.


The Role of HPV in Head and Neck Cancer Stem Cell Formation and Tumorigenesis.

Swanson MS, Kokot N, Sinha UK.

Cancers (Basel). 2016 Feb 19;8(2). pii: E24. doi: 10.3390/cancers8020024. Review.


Stochastic modeling reveals an evolutionary mechanism underlying elevated rates of childhood leukemia.

Rozhok AI, Salstrom JL, DeGregori J.

Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):1050-5. doi: 10.1073/pnas.1509333113. Epub 2016 Jan 11.


Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance.

Grimwade D, Ivey A, Huntly BJ.

Blood. 2016 Jan 7;127(1):29-41. doi: 10.1182/blood-2015-07-604496. Epub 2015 Dec 10. Review.


Prospective long-term minimal residual disease monitoring using RQ-PCR in RUNX1-RUNX1T1-positive acute myeloid leukemia: results of the French CBF-2006 trial.

Willekens C, Blanchet O, Renneville A, Cornillet-Lefebvre P, Pautas C, Guieze R, Ifrah N, Dombret H, Jourdan E, Preudhomme C, Boissel N; French AML Intergroup.

Haematologica. 2016 Mar;101(3):328-35. doi: 10.3324/haematol.2015.131946. Epub 2015 Dec 3.


Is lineage decision-making restricted during tumoral reprograming of haematopoietic stem cells?

Brown G, Sanchez-Garcia I.

Oncotarget. 2015 Dec 22;6(41):43326-41. doi: 10.18632/oncotarget.6145. Review.


Evolution of normal and neoplastic tissue stem cells: progress after Robert Hooke.

Weissman I.

Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19;370(1680):20140364. doi: 10.1098/rstb.2014.0364. Review.


Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia.

Klco JM, Miller CA, Griffith M, Petti A, Spencer DH, Ketkar-Kulkarni S, Wartman LD, Christopher M, Lamprecht TL, Helton NM, Duncavage EJ, Payton JE, Baty J, Heath SE, Griffith OL, Shen D, Hundal J, Chang GS, Fulton R, O'Laughlin M, Fronick C, Magrini V, Demeter RT, Larson DE, Kulkarni S, Ozenberger BA, Welch JS, Walter MJ, Graubert TA, Westervelt P, Radich JP, Link DC, Mardis ER, DiPersio JF, Wilson RK, Ley TJ.

JAMA. 2015 Aug 25;314(8):811-22. doi: 10.1001/jama.2015.9643.


Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?

Paietta E.

Clin Lymphoma Myeloma Leuk. 2015 Jun;15 Suppl:S2-6. doi: 10.1016/j.clml.2015.02.009.


Stem cells are units of natural selection for tissue formation, for germline development, and in cancer development.

Weissman IL.

Proc Natl Acad Sci U S A. 2015 Jul 21;112(29):8922-8. doi: 10.1073/pnas.1505464112.


Advancing the Minimal Residual Disease Concept in Acute Myeloid Leukemia.

Hokland P, Ommen HB, Mulé MP, Hourigan CS.

Semin Hematol. 2015 Jul;52(3):184-92. doi: 10.1053/j.seminhematol.2015.04.001. Epub 2015 Apr 7. Review.

Supplemental Content

Support Center